[fcb5af]: / literature / by_gene / CXCR4.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 33634586 10.1002/cyto.b.21995 2022 Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia. CXCR4
2 34115701 10.1097/RLU.0000000000003750 2022 Burkitt Lymphoma/Leukemia Presented on 68Ga-Pentixafor and 18F-FDG PET/CT. CXCR4
3 34525196 10.1182/blood.2021013239 2022 CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication. CXCR4
4 34651291 10.1007/s11307-021-01664-3 2022 CXCR4-Directed PET/CT with [<sup>68</sup>Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [<sup>18</sup>F]FDG PET/CT. CXCR4
5 34781809 10.1080/10428194.2021.2005045 2022 Plamotamab (XmAb<sup>®</sup>13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. CXCR4
6 34793256 10.1200/JCO.21.01194 2022 Venetoclax in Previously Treated Waldenström Macroglobulinemia. CXCR4
7 34980578 10.1016/j.clml.2021.11.014 2022 SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions. CXCR4
8 34990302 10.1080/21655979.2021.2017590 2022 Propofol induces the apoptosis of neural stem cells via microRNA-9-5p / chemokine CXC receptor 4 signaling pathway. CXCR4
9 35020191 10.1111/bjh.18036 2022 Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. CXCR4
10 35037561 10.1080/10428194.2021.2020776 2022 Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia. CXCR4
11 35057088 10.3390/pharmaceutics14010192 2022 Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. CXCR4
12 35078860 10.1158/1078-0432.CCR-21-3284 2022 Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands. CXCR4
13 35149375 10.1016/j.ctarc.2022.100527 2022 Current approach to Waldenström Macroglobulinemia. CXCR4
14 35149705 10.1038/s41598-022-05857-w 2022 Cell surface expression of GRP78 and CXCR4 is associated with childhood high-risk acute lymphoblastic leukemia at diagnostics. CXCR4
15 35181615 2022 Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications. CXCR4
16 35241482 10.2967/jnumed.121.263693 2022 Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using <sup>68</sup>Ga-PentixaFor PET. CXCR4
17 35255429 10.1016/j.anndiagpath.2021.151886 2022 De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients. CXCR4
18 35316324 10.1182/blood.2021014723 2022 Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. CXCR4
19 35339405 10.1016/j.clml.2022.02.005 2022 SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. CXCR4
20 35358350 10.1002/ajh.26552 2022 First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. CXCR4
21 35385630 2022 Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome? CXCR4
22 35421785 10.1016/j.biopha.2022.112940 2022 A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4<sup>+</sup> lymphoma cells without toxicity in immunocompromised and immunocompetent mice. CXCR4
23 35450208 10.1177/20406207221090886 2022 Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. CXCR4
24 35454017 10.3390/diagnostics12040969 2022 Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. CXCR4
25 35510210 10.1177/20406207221093962 2022 Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond. CXCR4
26 35522562 10.1002/path.5924 2022 CXCR4 mediates leukemic cell migration and survival in the testicular microenvironment. CXCR4
27 35608747 10.1007/s11033-022-07163-0 2022 Molecular effects of genistein, as a potential anticancer agent, on CXCR-4 and VEGF pathway in acute lymphoblastic leukemia. CXCR4
28 35674738 10.1007/s00259-022-05849-y 2022 CXCR4-targeted theranostics in oncology. CXCR4
29 35695746 10.1080/17474086.2022.2089110 2022 Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following <i>H. pylori</i> treatment? CXCR4
30 35738903 10.2967/jnumed.122.264207 2022 C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma. CXCR4
31 35770040 10.2147/TCRM.S338655 2022 Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First. CXCR4
32 35774848 10.1155/2022/3276925 2022 Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. CXCR4
33 35794478 10.1038/s41586-022-04906-8 2022 Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. CXCR4
34 35802888 10.1080/10428194.2022.2074986 2022 CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents. CXCR4
35 35842683 10.1186/s13287-022-03011-x 2022 Prostaglandin E1 reduces apoptosis and improves the homing of mesenchymal stem cells in pulmonary arterial hypertension by regulating hypoxia-inducible factor 1 alpha. CXCR4
36 35877223 10.3390/curroncol29070363 2022 Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. CXCR4
37 35884548 10.3390/cancers14143488 2022 Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review. CXCR4
38 35954476 10.3390/cancers14153814 2022 The Role of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review. CXCR4
39 36030395 10.1111/ejh.13856 2022 A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience. CXCR4
40 36048893 10.1093/ajcp/aqac104 2022 Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant. CXCR4
41 32733009 10.1038/s41375-020-0999-2 2021 Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination. CXCR4
42 32795528 10.1016/j.jid.2020.06.034 2021 Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4. CXCR4
43 32810857 10.1159/000509286 2021 Current and Emerging Treatments for Waldenström Macroglobulinemia. CXCR4
44 33131073 10.1111/exd.14228 2021 The role of Dipeptidyl Peptidase-4 in cutaneous disease. CXCR4
45 33206936 10.1182/blood.2020005650 2021 Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. CXCR4
46 33208624 10.1097/RLU.0000000000003404 2021 Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI. CXCR4
47 33253591 10.1021/acs.molpharmaceut.0c00785 2021 High-Contrast CXCR4-Targeted <sup>18</sup>F-PET Imaging Using a Potent and Selective Antagonist. CXCR4
48 33391493 10.7150/thno.48620 2021 CXCR4 PET imaging of mantle cell lymphoma using [<sup>68</sup>Ga]Pentixafor: comparison with [<sup>18</sup>F]FDG-PET. CXCR4
49 33555272 10.1172/JCI141566 2021 RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. CXCR4
50 33569985 10.1080/10428194.2021.1881514 2021 Clinical application of genomics in Waldenström macroglobulinemia. CXCR4
51 33579803 10.2967/jnumed.120.257279 2021 Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. CXCR4
52 33604348 10.3389/fmed.2021.609116 2021 YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial. CXCR4
53 33612450 10.1016/j.transci.2021.103070 2021 First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients. CXCR4
54 33660512 10.1021/acs.jmedchem.1c00066 2021 Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. CXCR4
55 33716502 10.2147/IJN.S289733 2021 Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4<sup>+</sup> Diffuse Large B-Cell Lymphoma Cells. CXCR4
56 33735664 10.1016/j.neo.2021.02.002 2021 Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. CXCR4
57 33743810 10.1186/s13045-021-01060-y 2021 Targeting chemokines for acute lymphoblastic leukemia therapy. CXCR4
58 33843403 10.1080/10428194.2021.1910684 2021 CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration. CXCR4
59 33856274 10.1080/10428194.2021.1913150 2021 Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma. CXCR4
60 33934404 10.1002/jcla.23784 2021 PCR array analysis identified hyperproliferation but not autophagy or apoptosis in fibrous epulis. CXCR4
61 34050566 10.1111/cpr.13076 2021 Role of CXCR4 in the progression and therapy of acute leukaemia. CXCR4
62 34083646 10.1038/s41598-021-91112-7 2021 DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity. CXCR4
63 34093792 10.7150/jca.54952 2021 Aggregative Perivascular Tumor Cell Growth Pattern of Primary Central Nervous System Lymphomas Is Associated with Hypoxia-Related Endoplasmic Reticulum Stress. CXCR4
64 34106998 10.1371/journal.ppat.1009618 2021 Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes. CXCR4
65 34122453 10.3389/fimmu.2021.688747 2021 Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure. CXCR4
66 34172595 10.1097/RLU.0000000000003760 2021 Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT. CXCR4
67 34187383 10.1186/s12876-021-01844-z 2021 Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report. CXCR4
68 34255748 10.1172/JCI143119 2021 Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. CXCR4
69 34269725 10.1097/RLU.0000000000003817 2021 CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma. CXCR4
70 34307181 10.3389/fonc.2021.710900 2021 Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes. CXCR4
71 34340248 10.1111/bjh.17691 2021 Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. CXCR4
72 34363012 10.1038/s41375-021-01376-1 2021 CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. CXCR4
73 34396983 10.1172/JCI151295 2021 All in for nuclear PFKP-induced CXCR4 metastasis: a T cell acute lymphoblastic leukemia prognostic marker. CXCR4
74 34404617 10.1016/j.transci.2021.103240 2021 An innovation in stem cell harvesting: Heparin use. CXCR4
75 34490994 10.1002/pbc.29319 2021 Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma. CXCR4
76 34570179 10.1182/bloodadvances.2021004668 2021 Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. CXCR4
77 34583709 10.1186/s12943-021-01419-2 2021 Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma. CXCR4
78 34635806 10.1038/s41423-021-00775-9 2021 Posttransplant blockade of CXCR4 improves leukemia complete remission rates and donor stem cell engraftment without aggravating GVHD. CXCR4
79 34714390 10.1186/s13550-021-00852-0 2021 Semi-quantitative measurements of chemokine receptor 4-targeted <sup>68</sup>Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. CXCR4
80 34722241 10.3389/fonc.2021.692788 2021 Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value. CXCR4
81 34793563 10.1371/journal.pone.0260186 2021 Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach. CXCR4
82 34990523 10.4143/crt.2021.944 2021 Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia During R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma. CXCR4
83 35028611 10.1016/j.xcrm.2021.100470 2021 Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system. CXCR4
84 35087759 10.3389/fonc.2021.801124 2021 Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia. CXCR4
85 31248974 10.3324/haematol.2018.211490 2020 A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. CXCR4
86 31260155 10.1002/jmri.26848 2020 MRI and PET/MRI in hematologic malignancies. CXCR4
87 31471373 10.3324/haematol.2019.216218 2020 CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. CXCR4
88 31476465 10.1016/j.wneu.2019.08.140 2020 T140 Inhibits Apoptosis and Promotes Proliferation and Matrix Formation Through the SDF-1/CXC Receptor-4 Signaling Pathway in Endplate Chondrocytes of the Rat Intervertebral Discs. CXCR4
89 31561267 10.1002/1873-3468.13623 2020 Single-cell RNA sequencing reveals chemokine self-feeding of myeloma cells promotes extramedullary metastasis. CXCR4
90 31571524 10.1080/15384047.2019.1665405 2020 CXCR4-targeted PET imaging using <sup>64</sup>Cu-AMD3100 for detection of Waldenström Macroglobulinemia. CXCR4
91 31605845 10.1016/j.wneu.2019.09.158 2020 Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation. CXCR4
92 31719683 10.1038/s41375-019-0628-0 2020 Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma. CXCR4
93 31726164 10.1016/j.ijbiomac.2019.09.157 2020 Degraded fucoidan fractions and β-1,3-glucan sulfates inhibit CXCL12-induced Erk1/2 activation and chemotaxis in Burkitt lymphoma cells. CXCR4
94 31768009 10.1038/s41409-019-0756-1 2020 The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. CXCR4
95 31809874 10.1016/j.cellsig.2019.109492 2020 Ghrelin induces autophagy and CXCR4 expression via the SIRT1/AMPK axis in lymphoblastic leukemia cell lines. CXCR4
96 31902622 10.1016/j.pathol.2019.11.002 2020 A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. CXCR4
97 31960730 10.1080/10428194.2020.1711901 2020 Waldenstrom's macroglobulinemia in the era of immunotherapy. CXCR4
98 31980558 10.1136/jclinpath-2019-206282 2020 Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS. CXCR4
99 32006301 10.1007/s11899-020-00559-4 2020 Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. CXCR4
100 32083995 10.1200/JCO.19.02314 2020 Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. CXCR4